Ascendis Pharma A/S Share Price

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/07/2024 BST 5-day change 1st Jan Change
138.6 USD -1.58% Intraday chart for Ascendis Pharma A/S +0.90% +10.02%

Financials

Sales 2024 * 423M 462M 35.58B Sales 2025 * 710M 776M 59.72B Capitalization 7.27B 7.94B 611B
Net income 2024 * -299M -327M -25.15B Net income 2025 * -18M -19.67M -1.51B EV / Sales 2024 * 18.2 x
Net Debt 2024 * 440M 481M 36.99B Net Debt 2025 * 405M 443M 34.1B EV / Sales 2025 * 10.8 x
P/E ratio 2024 *
-24.5 x
P/E ratio 2025 *
-212 x
Employees 879
Yield 2024 *
-
Yield 2025 *
-
Free-Float 10.15%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada MT
Pendopharm Signs Exclusive Distribution Agreement with Ascendis Pharma A/S for TransCon PTH in Canada CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading MT
TD Cowen Upgrades Ascendis Pharma to Buy Rating With $175 Price Target MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT
Transcript : Ascendis Pharma A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
More news
1 day-1.58%
1 week+0.90%
Current month+1.61%
1 month+11.22%
3 months-2.53%
6 months+4.66%
Current year+10.02%
More quotes
1 week
135.23
Extreme 135.23
142.21
1 month
121.07
Extreme 121.07
142.21
Current year
116.63
Extreme 116.625
161.00
1 year
85.29
Extreme 85.285
161.00
3 years
61.58
Extreme 61.5791
178.71
5 years
61.58
Extreme 61.5791
183.98
10 years
11.92
Extreme 11.92
183.98
More quotes
Managers TitleAgeSince
Founder 65 31/08/06
Director of Finance/CFO 50 07/08/16
Chief Tech/Sci/R&D Officer 50 30/04/20
Members of the board TitleAgeSince
Founder 65 31/08/06
Chairman 51 31/10/14
General Counsel 53 31/12/07
More insiders
Date Price Change Volume
17/07/24 138.6 -1.58% 261,854
16/07/24 140.8 +2.74% 498,011
15/07/24 137 -0.75% 327,109
12/07/24 138.1 +1.75% 429,310
11/07/24 135.7 -1.19% 416,520

Delayed Quote Nasdaq, July 17, 2024 at 09:00 pm

More quotes
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
126.7 EUR
Average target price
167.1 EUR
Spread / Average Target
+31.89%
Consensus